Drugs / LY3962673
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06586515 | Sep 2024 → Mar 2029 expected | colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Eli Lilly and Company | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3962673 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06586515 ↗ |
| Route | Oral | “Escalating doses of LY3962673 administered orally.” NCT06586515 ↗ |